Immunogenicity and safety after the third vaccination with the 23-valent pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease-Reference-Cited by-同舟云学术

Immunogenicity and safety after the third vaccination with the 23-valent pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease

Published:2020-02-12 Issue:9 Volume:16 Page:2285-2291
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Ohshima Nobuharu¹^ORCID,Akeda Yukihiro²,Nagai Hideaki¹,Oishi Kazunori³⁴

Affiliation:

1. Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan

2. Department of Infection Control and Prevention, Graduate School of Medicine, Osaka University, Osaka, Japan

3. Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan

4. Department of Bacteriology, Toyama Institute of Health, Toyama, Japan

Funder

Japan Agency for Medical Research and Development

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2020.1718975

Reference25 articles.

1. Community-Acquired Pneumonia

2. The JRS Guidelines for the Management of Community-acquired Pneumonia in Adults:An Update and New Recommendations

3. Effects of Pneumococcal Conjugate Vaccine on Genotypic Penicillin Resistance and Serotype Changes, Japan, 2010–2017

4. Emergence of Streptococcus pneumoniae Serotype 12F after Sequential Introduction of 7- and 13-Valent Vaccines, Israel

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult;Frontiers in Public Health;2023-06-29

2. Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature;Expert Review of Vaccines;2021-03-02